Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of mesenchymal stem cell migration. [GO_REF:0000058, GOC:TermGenie, PMID:26846297]
Positive regulation of mesenchymal stem cell migration is a complex process involving a coordinated interplay of signaling pathways, extracellular matrix interactions, and cytoskeletal rearrangements. The process is initiated by the binding of chemoattractant molecules to specific receptors on the surface of mesenchymal stem cells. These receptors trigger intracellular signaling cascades, such as the PI3K/AKT and MAPK pathways, leading to the activation of transcription factors and the upregulation of genes involved in cell motility. Concurrently, the extracellular matrix surrounding the cells is remodeled, providing a scaffold for cell migration. Integrins, transmembrane proteins that link the cell to the extracellular matrix, play a crucial role in this process. They mediate cell adhesion, migration, and differentiation. Upon binding to specific ligands in the extracellular matrix, integrins initiate intracellular signaling cascades that regulate cytoskeletal dynamics. Actin filaments are reorganized into filopodia and lamellipodia, which extend outwards and probe the environment for suitable migratory paths. The leading edge of the migrating cell adheres to the extracellular matrix, while the trailing edge detaches and retracts. This coordinated movement, driven by cytoskeletal reorganization, propels the cell forward. The process is further fine-tuned by various signaling molecules, including chemokines, growth factors, and cytokines, which influence cell directionality and speed. Overall, positive regulation of mesenchymal stem cell migration involves a precise orchestration of signaling pathways, extracellular matrix interactions, and cytoskeletal rearrangements. This intricate process ensures the efficient and directed movement of these cells, enabling them to respond to specific cues and contribute to tissue repair and regeneration.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| C-X-C chemokine receptor type 4 | A C-X-C chemokine receptor type 4 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P61073] | Homo sapiens (human) |
| Atypical chemokine receptor 3 | An atypical chemokine receptor 3 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25106] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| zalcitabine | zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase. Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. | pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor |
| plerixafor | plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2 | azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound | anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant |
| benzylaniline | benzylaniline: major metabolite of antazoline; RN given refers to parent cpd | ||
| terephthalamide | benzenedicarboxamide | ||
| krh 1636 | KRH 1636: structure in first source | ||
| amd 8664 | |||
| cyclo(d-tyrosyl-arginyl-arginyl-3-(2-naphthyl)alanyl-glycyl) | oligopeptide | ||
| amd 070 | mavorixafor: a derivative of AMD3100; a CXCR4 blocker | aminoquinoline | |
| wz 811 | |||
| tn14003 | TN14003: synthetic antagonist 14-mer peptide inhibiting metastasis in an animal model |